Roth Capital Comments on Buy-Rated Galena (GALE) Following CEO Transition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/16/2026
- S&P 500, Nasdaq set for lower open as chip weakness weighs
- TSMC Q2 profit jumps 77% to record, far surpasses expectations
- Oil rises over 1% as Iran threat puts Red Sea route at risk
- Citi sees Google, Meta and Amazon capex spending at over $800 billion in 2027
- UnitedHealth shares surge on strong earnings beat and guidance
Galena Biopharma Appoints Mark W. Schwartz, Ph.D., as President and Chief Executive Officer
August 21, 2014 7:05 AM EDTPORTLAND, Ore., Aug. 21, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq: GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that Mark W. Schwartz, Ph.D., has been appointed as President and Chief Executive Officer, effective immediately. Dr. Schwartz was previously Galena's Executive Vice President and Chief Operating Officer. He replaces Mark J. Ahn, Ph.D. who has resigned as the President and CEO and as a director of the company to pursue other long held personal and... More
